Emergent BioSolutions Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph C. Papa
- Full Time Employees
- 900
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 400 Professional Drive Gaithersburg MD United States 20879
- IPO Date
- Nov 15, 2006
- CIK
- 0001367644
- Website
- emergentbiosolutions.com
- Similar Companies
- Business
- Emergent BioSolutions Inc. (EBS) develops, manufactures and commercializes vaccines, therapeutics and medical countermeasures addressing public health threats including infectious diseases, opioid overdoses and biodefense risks; its core products encompass NARCAN Nasal Spray 4 mg (naloxone HCl, the first FDA-approved over-the-counter opioid overdose reversal agent), KLOXXADO Nasal Spray 8 mg (naloxone HCl), ACAM2000 (Smallpox (Vaccinia) Vaccine, Live, also indicated for mpox), BioThrax (Anthrax Vaccine Adsorbed), CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)), BAT (Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – Equine), CNJ-016 (vaccinia immune globulin intravenous, human), raxibacumab (fully human monoclonal antibody for anthrax), Ebanga (ansuvimab-zykl for Ebola), and TEMBEXA (brincidofovir for smallpox; distributed pursuant to collaboration with Ridgeback Therapeutics). The company operates through three segments: Commercial Products (opioid reversal agents and related offerings), Medical Countermeasures (MCM) Products (anthrax, smallpox, botulism, Ebola and other biothreat solutions procured primarily by governments) and Services (contract development and manufacturing for biopharma partners). Founded in 1998 as BioPort Inc. through acquisition of Michigan Biologic Products Institute and renamed Emergent BioSolutions in 2004, it maintains headquarters in Gaithersburg, Maryland, with manufacturing facilities including sites in Baltimore, Maryland; Lansing, Michigan; and Bayview, Maryland; it serves civilian, military and government customers globally, with key markets in the United States, Canada and international public health agencies. Recent developments include an October 2025 investment agreement and strategic partnership with RocketVax Ltd. to lead U.S. manufacturing and commercialization of four next-generation vaccine candidates for infectious diseases, cancer and autoimmune disorders (one backed by a U.S. National Institutes of Health Project NextGen letter of intent); eleven U.S. government MCM contract modifications and product orders secured in 2025 totaling hundreds of millions of dollars for products including CYFENDUS, ACAM2000, VIGIV and BAT; a $65 million multi-year contract with the Ontario Ministry of Health for NARCAN Nasal Spray; approximately $550 million in additional MCM contract modifications; repayment of $168 million in debt and a new $250 million term loan to bolster financial position; completion of the $30 million sale of its Baltimore-Camden manufacturing site to Bora Pharmaceuticals in August 2024 as part of a multi-year transformation plan involving cost savings of $80 million annually through workforce reductions and facility closures; and divestiture of RSDL (Reactive Skin Decontaminant Lotion) to SERB Pharmaceuticals for $75 million in July 2024.
Company News
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript
Emergent Biosolutions Q3 Earnings Call Highlights
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Russian plague outbreak could boost these under-the-radar pharma stocks
Emergent Biosolutions (NYSE:EBS) Stock: Insider Paul Anthony Williams Sells 3,000 Shares
Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Price Target of $10.00
Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
BlackRock Inc. Invests $39.52 Million in Emergent Biosolutions Inc. $EBS